On Monday, shares of Synergy Resources Corp (NYSEMKT:SYRG), included 4.15 % and shut at $8.54 inside the end purchasing and offering session. The last exchanging scope of the stock ranges amongst $8.34 and $8.56. Synergy Resources Corporation engages in the acquisition, development, exploitation, exploration, and production of oil and natural gas properties mainly located in the Denver-Julesburg Basin in Colorado. As of December 31, 2015, the company had about 349,000 net acres under lease, which are located in the Wattenberg Field of the Denver-Julesburg Basin; and operated 369 net producing wells.
Shares of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), subtract -3.20% and shut at $13.61 inside the last exchanging session. The rest of the purchasing and offering scope of the stock levels among $13.57 and $14.03. The association’s commercial center capitalization is $2.68 Billion with the general uncommon loads of 194.20 million. ARIAD Pharmaceuticals, Inc. (ARIA), a rare cancer-focused innovative biotechnology company, recently declared that clinical data on brigatinib, its investigational anaplastic lymphoma kinase (ALK) inhibitor, will be presented at the International Association for the Study of Lung Cancer (IASLC) 17th World Conference on Lung Cancer (WCLC) being held in Vienna, December 4 to 7, 2016.
“We are excited that updated data from the ALTA trial on brigatinib in patients with ALK-positive non-small cell lung cancer will be presented at WCLC this year. We continue to be encouraged by the activity and safety profile seen in the ALTA trial, and especially the correlation between investigator and independent review assessments of response and response durability. ALTA data to be presented at the meeting will include about three months of additional follow-up as contrast to the abstract,” stated Timothy P. Clackson, Ph.D., president of research and development and chief scientific officer at ARIAD.